A network meta-analysis comparing alemtuzumab to natalizumab in patients with relapsing-remitting multiple sclerosis with rapidly evolving severe disease

被引：0
|
作者：
Guo, J. D. [1 ]
Das Gupta, R. J. [1 ]
Fahrbach, K. [2 ]
Wissinger, E. [2 ]
Cox, F. M. [1 ]
机构：
[1] Sanofi Genzyme, Cambridge, MA USA
[2] Evidera, Bethesda, MD USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1479
引用
收藏
页码：772 / 772
页数：1
相关论文
共 50 条
  • [41] Effect of alemtuzumab on quality of life in patients with relapsing-remitting multiple sclerosis
    Bass, Ann
    MULTIPLE SCLEROSIS, 2009, 15 (11): : 1396 - 1396
  • [42] Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis A meta-analysis
    Landmeyer, Nils C.
    Buerkner, Paul-Christian
    Wiendl, Heinz
    Ruck, Tobias
    Hartung, Hans-Peter
    Holling, Heinz
    Meuth, Sven G.
    Johnen, Andreas
    NEUROLOGY, 2020, 94 (22) : E2373 - E2383
  • [43] Neuropsychological evaluation in patients with relapsing-remitting multiple sclerosis receiving natalizumab: a retrospective analysis
    Edwards, Keith R.
    Goodman, William
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (08) : 1016 - 1016
  • [44] NATALIZUMAB FOR RAPIDLY EVOLVING SEVERE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RESRMS) PATIENTS: 5-YEAR BUDGET IMPACT ANALYSIS (BIA) FROM THE BRAZILIAN PUBLIC PAYER PERSPECTIVE
    Nishikawa, A. M.
    Paladini, L.
    Liamas, A. L.
    Bueno, C. C.
    Clark, O. A. C.
    VALUE IN HEALTH, 2013, 16 (07) : A621 - A621
  • [45] Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)
    Gallagher, P. J.
    McGuigan, C.
    Nicholas, R.
    Hobart, J.
    Ford, H.
    Petheram, K.
    Sharrack, B.
    Robertson, N.
    Mazibrada, G.
    Scolding, N.
    Wilson, M.
    Pearson, O.
    Silber, E.
    Rog, D.
    Turner, B.
    Harikrishnan, S.
    Duddy, M.
    Gray, O.
    Jones, J.
    Overell, J.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 357 - 358
  • [46] Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis
    Prosperini, L.
    Mancinelli, C. R.
    Gianni, C.
    Barletta, V.
    Fubelli, F.
    Borriello, G.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 469 - 470
  • [47] Natalizumab: A guide to its use in relapsing-remitting multiple sclerosis
    Keating G.M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2014, 30 (2) : 48 - 54
  • [48] Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis
    Perini, P.
    Rinaldi, F.
    Rinaldi, L.
    Calabrese, M.
    Gallo, P.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S234 - S234
  • [49] Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis
    Rinaldi, Francesca
    Perini, Paola
    Calabrese, Massimiliano
    Rinaldi, Luciano
    Gallo, Paolo
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (11) : 1359 - 1362
  • [50] Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis
    Brown, J. William L.
    Coles, Alasdair J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 131 - 138
12345